Lavaca Capital’s AbbVie ABBV Stock Holding History

Lavaca Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-8,600	Closed	-$1.32M	–	134
2022 Q2	$1.32M	Sell	8,600 -700	-8%	-$107K	0.2%	52
2022 Q1	$1.51M	Sell	9,300 -200	-2%	-$29.1K	0.16%	67
2021 Q4	$1.29M	Sell	9,500 -300	-3%	-$35.4K	0.17%	71
2021 Q3	$1.06M	Hold	9,800	–	–	0.11%	89
2021 Q2	$1.1M	Buy	+9,800	New	+$1.1M	0.11%	78

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Lavaca Capital's ABBV Position: Q2 2026 in Review

Lavaca Capital increased its AbbVie (ABBV) stake by 30% in Q2 2026, buying an estimated $140K and bringing the position to 2,819 shares worth $709K. The position accounts for 0.07% of the portfolio, ranked #70.

Lavaca Capital first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. The position peaked at $8.54M in Q2 2021. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Lavaca Capital held 2,819 shares of AbbVie worth $709K as of Q2 2026.
Lavaca Capital bought 650 AbbVie shares in Q2 2026, an estimated $140K.
AbbVie made up 0.07% of Lavaca Capital's portfolio in Q2 2026, its #70 holding.
Lavaca Capital first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
Lavaca Capital's AbbVie position peaked at $8.54M in Q2 2021.
4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Lavaca Capital's 13F filing for Q2 2026, filed 14 Aug 2026.